Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms

Azacitidine is a mainstay of therapy for myelodysplastic syndrome (MDS)–related diseases. The purpose of our study is to elucidate the effect of gene mutations on hematological response and overall survival (OS), particularly focusing on their posttreatment clone size. We enrolled a total of 449 pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Nannya, Yasuhito, Tobiasson, Magnus, Sato, Shinya, Bernard, Elsa, Ohtake, Shigeki, Takeda, June, Creignou, Maria, Zhao, Lanying, Kusakabe, Manabu, Shibata, Yuhei, Nakamura, Nobuhiko, Watanabe, Mizuki, Hiramoto, Nobuhiro, Shiozawa, Yusuke, Shiraishi, Yuichi, Tanaka, Hiroko, Yoshida, Kenichi, Kakiuchi, Nobuyuki, Makishima, Hideki, Nakagawa, Masahiro, Usuki, Kensuke, Watanabe, Mitsumasa, Imada, Kazunori, Handa, Hiroshi, Taguchi, Masataka, Kiguchi, Toru, Ohyashiki, Kazuma, Ishikawa, Takayuki, Takaori-Kondo, Akifumi, Tsurumi, Hisashi, Kasahara, Senji, Chiba, Shigeru, Naoe, Tomoki, Miyano, Satoru, Papaemanuil, Elli, Miyazaki, Yasushi, Hellström-Lindberg, Eva, Ogawa, Seishi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Myeloid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10365941/
https://www.ncbi.nlm.nih.gov/pubmed/36989067
http://dx.doi.org/10.1182/bloodadvances.2022009564

Ejemplares similares

Ejemplares similares